India, June 9 -- Cartesian Therapeutics, Inc. (RNAC) shares surged 23.56 percent, gaining $1.39 to $7.25 on Tuesday after the late clinical-stage biotechnology company announced a strategic licensing agreement with WestGene Biopharma to advance the development of novel in vivo CAR-T therapies for autoimmune diseases.
The stock is currently trading at $7.25, compared with its previous close of $5.86 on the Nasdaq. During the session, it opened at $7.01 and traded between $7.00 and $9.33. Trading volume reached 2.57 million shares, significantly above its average volume of 172,425 shares.
The partnership is designed to combine Cartesian's expertise in autoimmune cell therapies with WestGene's targeted lipid nanoparticle delivery platform, p...